T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
about
Microfluidic enrichment for the single cell analysis of circulating tumor cells.HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancerCirculating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer TypesReduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib.Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyThe application of real-time PCR technique to detect rare cell clones with primary T790M Substitution of EGFR gene in metastases of non-small cell lung cancer to central nervous system in chemotherapy naive patients.Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.The epidermal growth factor receptor (EGFR / HER-1) gatekeeper mutation T790M is present in European patients with early breast cancer.Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung CancerMechanisms of resistance to EGFR tyrosine kinase inhibitors.Personalized targeted therapy for lung cancer244-MPT overcomes gefitinib resistance in non-small cell lung cancer cellsMechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study.Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer.miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.Non-small cell lung cancer: the era of targeted therapy.Multiplexed tyrosine kinase activity detection in cancer cells using a hydrogel immobilized substrateIs T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)?Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors.A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition.The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma.[Advanced research on T790M mutation in non-small cell lung cancer].Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.[Effects of tumor suppressor gene TCF21 on the proliferation, migration and apoptosis of A549 cells].
P2860
Q27340255-03B1FACA-E8A9-47A7-BC8E-BABD0DE73D83Q27852057-97168E95-8173-43E8-9134-6A880DA016A0Q28079253-8142D2C5-04C6-4B87-A1DA-07D0F82E8338Q33673752-1ADF0978-8EB0-4C1E-8701-E61B802923F9Q33684793-DE40E9E9-F553-4DD3-9BD7-48D785C7057EQ33693476-F3245DF3-24EE-46ED-950B-7B81BA75632CQ33700689-9D00F502-9DFD-449D-8F14-B0DA20ADCA99Q33757134-89332431-499D-4906-923B-89E3AE9D547AQ34253217-53E0A7F8-FA35-4DE3-8E09-6DA5A401215DQ34774462-B7E97802-77B0-4CFF-B108-56C38170677FQ35744220-3405C22D-FE67-40E6-A94A-3512AD7647A1Q36148697-15C7005F-05D9-4FF8-8476-92371213363BQ36238664-56DD2E5B-6AA1-4A5E-BE2B-FA4698E75F5DQ36321826-36C29962-1838-4B24-8317-A8029D5C1E5BQ36688956-22626BE9-BCEC-4E2C-AF76-AFF351A12DCEQ36942619-006D2BC9-7A69-4225-B681-4FBBA834838FQ37060387-1BC0FA9B-B888-47EC-B4A2-03568E40519FQ37349495-BF19E2C0-587C-404F-BF6B-DE2A76587E15Q37564535-30CB3489-EAA9-4692-AE25-CA448B31497FQ37645231-A27C7474-23B6-493A-9A0B-D703BE1AFD80Q39159197-5DE17583-0C9C-4CC3-B1EE-70005CE1FBC8Q40341970-A0C4D3CC-5656-4940-9185-409821BC45BAQ40855875-6BBACF8D-6E49-4195-A307-2BF2F1C21816Q41563298-0284CE2C-71F9-4B01-A5A3-2409B3AD5149Q41612540-1891BCB5-FB8C-4681-9824-5A1319B101CDQ47135157-F243B88C-C745-4C82-9A25-2622EA866D6EQ51738393-68D14FFF-D618-451A-82A6-050B60772A37Q52597593-ECB3CCFE-41D7-4C36-B6EA-5278F5C0BCD4Q53718494-9DB4E3ED-2862-4486-A4BC-C8149A634ED0Q54425335-1D2D3DE9-5931-4019-A1EB-029B945A0452Q55025386-390FE513-0B30-45B9-AB0E-F0EF94A63383Q55451366-A2EF3592-DA43-4FEE-A42F-764C9C248EB0
P2860
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
@ast
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
@en
type
label
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
@ast
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
@en
prefLabel
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
@ast
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
@en
P2093
P2860
P1476
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
@en
P2093
Chunyan Ma
Shuzhen Wei
P2860
P356
10.3978/J.ISSN.2072-1439.2010.12.02
P577
2011-03-01T00:00:00Z